WO2015001488A1 - Comprimés de palipéridone à libération prolongée et procédés de préparation - Google Patents

Comprimés de palipéridone à libération prolongée et procédés de préparation Download PDF

Info

Publication number
WO2015001488A1
WO2015001488A1 PCT/IB2014/062772 IB2014062772W WO2015001488A1 WO 2015001488 A1 WO2015001488 A1 WO 2015001488A1 IB 2014062772 W IB2014062772 W IB 2014062772W WO 2015001488 A1 WO2015001488 A1 WO 2015001488A1
Authority
WO
WIPO (PCT)
Prior art keywords
paliperidone
extended
layer
polymers
osmagents
Prior art date
Application number
PCT/IB2014/062772
Other languages
English (en)
Inventor
Balaram Mondal
Sandeep Kumar VATS
Kalaiselvan Ramaraju
Romi Barat Singh
Ajay Kumar Singla
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2015001488A1 publication Critical patent/WO2015001488A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to extended-release tablets of paliperidone. It further relates to processes for the preparation of the extended-release tablets and methods of treating neurological disorders by administering the extended-release tablets of paliperidone.
  • Paliperidone disclosed in U.S. Patent No. 5,158,952, is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives, and is an active metabolite of risperidone.
  • 2004/010981 discloses the need to have extended-release pharmaceutical compositions of paliperidone instead of immediate-release pharmaceutical compositions.
  • PCT Publication No. WO 1998/06380 discloses push-pull osmotic dosage forms providing ascending drug-release rates comprising a trilayered core composition, consisting of a first drug layer, a second drug layer, and a push layer.
  • U.S. Publication No. 2005/0025831 discloses push-pull osmotic dosage forms having one or more drug layers and a push layer wherein the different layers are compressed together to provide a longitudinally compressed capsule shaped tablet.
  • U.S. Publication No. 2009/0202631 teaches trilayered or capsule shaped osmotic dosage forms of paliperidone comprising a first drug layer, a second drug layer, and a push layer, with the limitation of having an osmagent in the first drug layer and no osmagent in the second drug layer.
  • the present invention relates to extended-release tablets of paliperidone which provide the desired ascending rate of release over a prolonged period of time and are bioequivalent to commercially available Invega ® tablets.
  • the present invention includes extended-release tablets of paliperidone comprising a trilayered core comprising two drug layers and a push layer, and an extended-release coating, wherein both of the drug layers comprise osmagents. It further includes extended-release tablets of paliperidone comprising a trilayered core comprising two drug layers and a push layer, a seal coating layer, and an extended-release coating, wherein the seal coating layer comprises an osmagent.
  • the present invention includes processes for preparing extended-release tablets of paliperidone. It also includes methods of treating and/or preventing neurological disorders by administering the extended-release tablets of paliperidone.
  • the extended-release tablets of the present invention are designed to be a once-a- day stable dosage form providing the desired in-vitro and in-vivo release profiles.
  • the first drug layer has a tendency not to mix into the second drug layer.
  • different release profiles are obtained. It is imperative to identify the optimum viscosity for each layer.
  • viscosity is modulated by the addition of an osmagent in both drug layers.
  • a first aspect of the present invention provides an extended-release tablet of paliperidone comprising:
  • a core comprising: (i) a first drug layer comprising paliperidone, one or more rate-controlling polymers, and one or more osmagents;
  • a second drug layer comprising paliperidone, one or more rate- controlling polymers, and one or more osmagents
  • a push layer comprising one or more fluid-expandable polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • an extended-release tablet of paliperidone comprising:
  • a first drug layer comprising paliperidone, polyethylene oxide having a molecular weight of about 200,000 to about 5,000,000, and one or more osmagents;
  • a second drug layer comprising paliperidone, polyethylene oxide having a molecular weight of about 200,000 to about 5,000,000, and one or more osmagents;
  • a push layer comprising polyethylene oxide having a molecular weight of about 5,000,000 to about 10,000,000 and one or more osmagents;
  • membrane-forming polymers with at least one passageway.
  • the present invention provides an extended-release tablet of paliperidone in which the structure of the tablet consists essentially of or consists of:
  • a core comprising: (i) a first drug layer comprising paliperidone, one or more rate-controlling polymers, and one or more osmagents;
  • a second drug layer comprising paliperidone, one or more rate- controlling polymers, and one or more osmagents
  • a push layer comprising one or more fluid-expandable polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • a second aspect of the present invention provides an extended-release tablet of paliperidone comprising:
  • a first drug layer comprising paliperidone and one or more rate- controlling polymers
  • a push layer comprising one or more fluid-expandable polymers and one or more osmagents
  • a seal coating layer comprising one or more film-forming polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • an extended-release tablet of paliperidone comprising:
  • a first drug layer comprising paliperidone and polyethylene oxide having a molecular weight of about 200,000 to about 5,000,000
  • a second drug layer comprising paliperidone and polyethylene oxide having a molecular weight of about 200,000 to about 5,000,000
  • a push layer comprising polyethylene oxide having a molecular weight of about 5,000,000 to about 10,000,000, and one or more osmagents;
  • a seal coating layer comprising one or more film-forming polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • the present invention provides an extended-release tablet of paliperidone in which the structure of the tablet consists essentially of or consists of:
  • a first drug layer comprising paliperidone and one or more rate- controlling polymers
  • a push layer comprising one or more fluid-expandable polymers and one or more osmagents
  • a seal coating layer comprising one or more film-forming polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • a third aspect of the present invention provides a process for the preparation of an extended-release tablet of paliperidone, wherein the process comprises the steps of:
  • step (d) dispersion of one or more film-forming polymers and other coating additives over the trilayered tablet core of step (d) to form a seal coating layer;
  • step (f) applying a coating composition comprising a solution or dispersion of one or more semi-permeable membrane-forming polymers and other coating additives over the tablet of step (d) or the seal coating layer of step (e) to form an extended-release coating;
  • a fourth aspect of the present invention provides a process for the preparation of an extended-release tablet of paliperidone, wherein the process comprises the steps of:
  • step (e) applying a coating composition comprising a solution or dispersion of one or more film-forming polymers, one or more osmagents, and other coating additives over the trilayered tablet core of step (d) to form a seal coating layer;
  • step (f) applying a coating composition comprising a solution or dispersion of one or more semi-permeable membrane-forming polymers and other coating additives over the seal coating layer of step (e) to form an extended-release coating;
  • a fifth aspect of the present invention provides a method of treating and/or preventing neurological disorders by administering an extended-release tablet of paliperidone comprising:
  • a first drug layer comprising paliperidone, one or more rate-controlling polymers, and one or more osmagents
  • a second drug layer comprising paliperidone, one or more rate- controlling polymers, and one or more osmagents
  • a push layer comprising one or more fluid-expandable polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • a sixth aspect of the present invention provides a method of treating and/or preventing neurological disorders by administering an extended-release tablet of paliperidone comprising:
  • a first drug layer comprising paliperidone and one or more rate- controlling polymers
  • a second drug layer comprising paliperidone and one or more rate- controlling polymers; and (iii) a push layer comprising one or more fluid-expandable polymers and one or more osmagents;
  • a seal coating layer comprising one or more film-forming polymers and one or more osmagents
  • membrane-forming polymers with at least one passageway.
  • a method of treating and/or preventing neurological disorders by administering an extended-release tablet of paliperidone, wherein the neurological disorders are selected from schizophrenia and bipolar mania.
  • a method of treating and/or preventing neurological disorders by administering an extended-release tablet of paliperidone, wherein the method comprises co-administration of additional drugs acting on the central nervous system.
  • extended-release refers to a dosage form comprising a drug which is formulated in such a way so as to provide a longer duration of
  • extended-release refers to the release of paliperidone over a prolonged period of time, for example, over a period of 6 hours, 8 hours, 12 hours, 16 hours, or 24 hours.
  • core refers to a trilayered compact composition comprising two drug layers and a push layer.
  • the trilayered compact composition of the present invention has a defined shape such as tablet, capsule, and the like. In particular, it is capsule shaped.
  • the extended-release tablet of paliperidone of the present invention provides the desired in-vitro and in-vivo release profile and is bioequivalent to that of the commercially available Invega ® tablet.
  • Bioequivalence is defined to mean the term used by the drug approval agencies, such as the US Food and Drug Administration: "the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.” This is typically understood to mean that the reference drug is within +25% and -20% of the reference drug product for AUC and C maX , for example as explained in the US FDA's various bioequivalence guidance documents for oral tablets and capsules, which are incorporated herein by reference.
  • the extended-release tablet of paliperidone of the present invention remains stable for a period of at least three months to the time extent necessary for the sale and use of the tablet.
  • paliperidone refers to ( ⁇ )-3-[2-[4-(6-fluoro-l,2- benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H- pyrido[l,2-a]pyrimidin-4-one. It further includes salts, polymorphs, enantiomers, hydrates, solvates, metabolites, prodrugs, chelates, and complexes thereof.
  • the present invention comprises paliperidone in an amount of from about 0.1% w/w to about 20% w/w of the total tablet weight. Further, the ratio of the amount of paliperidone in the first drug layer to the amount of paliperidone in the second drug layer ranges from about 0.1 : 1 to about 20: 1, in particular about 1 :3 to about 1 :6.
  • rate-controlling polymer refers to the agent that helps to control the release of paliperidone from the tablet.
  • Suitable examples of rate- controlling polymers are selected from the group consisting of polyalkylene oxides such as polyethylene oxide, polymethylene oxide, polybutylene oxide, and polyhexylene oxide having average molecular weight of about 100,000 to about 750,000; poly alkali carboxymethylcelluloses such as poly sodium carboxymethylcellulose, poly potassium carboxymethylcellulose, and poly lithium carboxymethylcellulose having an average molecular weight of about 40,000 to about 400,000; or mixtures thereof.
  • polyethylene oxide is a non-ionic homopolymer of the formula -(-0-CH2-CH2-) n -, wherein n represents the average number of oxyethylene groups, n generally being from about 2,000 to about 100,000 to 200,000. It is a water- soluble resin which is available as a white powder in several grades having different molecular weights which vary in viscosity profile when dissolved in water (National Formulary XVII, pp. 1963-1964 (1990)), Polyethylene oxide resin is commercially available under the trade name Polyox ® . It is available in various grades depending on its molecular weight, which may range from about 100,000 to about 7,000,000, including from about 200,000 to about 5,000,000.
  • suitable grades of polyethylene oxide include Polyox , Polyox WSRN-80 (molecular weight of 200,000), Polyox ® WSR N-750 (molecular weight of 300,000), Polyox ® WSR-205 (molecular weight of 600,000), Polyox ® WSR- 1105 (molecular weight of 900,000), Polyox ® WSR N-12K (molecular weight of 1,000,000), Polyox ® WSR N- 60K (molecular weight of 2,000,000), Polyox ® WSR-301 (molecular weight of
  • both drug layers comprise Polyox ® WSRN-80 having a molecular weight of about 200,000.
  • both drug layers of the present invention comprise rate-controlling polymers in an amount of more than about 30% w/w, and in particular more than about 40% w/w, of the total weight of each drug layer.
  • fluid-expandable polymer refers to an agent which, after interacting with water and/or aqueous biological fluids, is able to swell or expand.
  • the fluid-expandable polymers are employed in an effective amount that will control the swelling of the push layer.
  • Suitable examples of fluid-expandable polymers are selected from the group consisting of polyethylene oxide having an average molecular weight of about 5,000,000 to about 10,000,000; cellulose derivatives such as methyl cellulose, carboxymethyl cellulose and hydroxypropyl methylcellulose; poly(hydroxy alkyl methacrylate); poly(vinyl)alcohol having a low acetal residue; cross-linked agar; alginic acid and its derivatives/salts such as sodium alginate; a water-swellable copolymer produced by forming a dispersion of a finely divided copolymer of maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene; Carbopol ® having a molecular weight of 450,000 to 4,000,000; polyacrylamides; cross-linked water-swellable indane maleic anhydride polymers; Good-Rite ® polyacrylic acid having a molecular weight of 80,000 to 200,000; starch
  • the push layer comprises polyethylene oxide having an average molecular weig ht of about 7,000,000 available as Polyox ® WSR- 303.
  • the push layer of the present invention comprises a fluid-expandable polymer in an amount of more than about 10% w/w based on the total weight of the push layer.
  • osmagent includes all pharmaceutically acceptable, inert, water-soluble compounds that can imbibe water and/or aqueous biological fluids. Suitable examples of osmagents are selected from the group consisting of water-soluble salts of inorganic acids such as magnesium chloride, magnesium sulfate, lithium chloride, sodium chloride, potassium chloride, lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate, lithium dihydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; water-soluble salts of organic acids such as sodium acetate, potassium acetate, magnesium succinate, sodium benzoate, sodium citrate, and sodium ascorbate; carbohydrates such as mannitol, sorbitol, arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, and raffinose; water-soluble amino acids such as
  • both drug layers and the push layer comprise osmagent.
  • a seal-coating layer is present in between the trilayered core and the extended-release coating, and both the seal coat and the push layer comprise osmagent.
  • the osmagent in any of the layers is present in an amount of from about 1% w/w to about 40% w/w based on total weight of each layer.
  • pharmaceutically inert excipients includes all the excipients used in the art of manufacturing osmotic release dosage forms. Specific examples include binders, diluents, surfactants, pH modifiers, lubricants/glidants, stabilizers, and coloring agents.
  • binders are methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, povidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, or mixtures thereof.
  • diluents are calcium carbonate, calcium dibasic phosphate, calcium tribasic phosphate, calcium sulfate, microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sorbitol, starch, starch pregelatinized, sucrose, sugar compressible, sugar confectioners, or mixtures thereof.
  • surfactants include both non-ionic and ionic (cationic, anionic, and zwitterionic) surfactants suitable for use in pharmaceutical compositions.
  • Specific examples of surfactants polyethoxylated fatty acids and its derivatives such as polyethylene glycol (PEG) 400 distearate, PEG-20 dioleate, PEG 4-150 mono dilaurate, and PEG-20 glyceryl stearate; alcohol-oil transesterification products such as PEG- 6 corn oil; polyglycerized fatty acids such as polygly eery 1-6 pentaoleate; propylene glycol fatty acid esters such as propylene glycol monocaprylate; mono and diglycerides such as glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and their derivatives such as PEG-20 sorbitan monooleate and sorbitan monolaurate; polyethylene glycol alkyl ether or phenols such as
  • the pH modifiers are substances which maintain the pH of the local environment surrounding the drug at a value favorable for dissolution of the drug.
  • Specific examples of pH modifiers are dibasic sodium phosphate, sodium ascorbate, meglumine, sodium citrate, trimethanolamine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium oxide, magnesium hydroxide, ammonia, tertiary sodium phosphate, diethanolamine, ethylenediamine, L-lysine, or mixtures thereof.
  • lubricants/glidants are colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, or mixtures thereof.
  • Stabilizers include antioxidants, buffers, acids, or mixtures thereof. Suitable antioxidants are selected from the group consisting of butylated hydroxyl anisole, butylated hydroxyl toluene, sodium metabisulfite, ascorbic acid, ascorbyl palmitate, thiourea, acetylcysteine, dithiothreitol, cysteine hydrochloride, propyl gallate, tocopherol, or mixtures thereof.
  • Coloring agents include any FDA approved colors for oral use, for example, iron red oxide.
  • the seal-coating layer is applied over the trilayered core and comprises one or more film-forming polymers, one or more osmagents, and coating additives.
  • Suitable examples of film-forming polymers are selected from the group consisting of hydroxyl ethyl cellulose, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, waxes such as polyethylene glycol, and methacrylic acid polymers such as Eudragit .
  • commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry ® , may also be used.
  • extended-release coating refers to a coating which allows movement of water molecules through it but does not allow the contents of the core to pass through.
  • the extended-release coating of the present invention comprises semipermeable membrane -forming polymers, flux enhancers, film-forming polymers, and other coating additives.
  • Semi-permeable membrane-forming polymers pass through the gastrointestinal tract unchanged and are eliminated in feces.
  • Suitable examples of semi-permeable membrane -forming polymers are selected from the group consisting of cellulose derivatives such as cellulose acetate, ethyl cellulose, cellulose triacetate, agar acetate, amylose acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate
  • Flux enhancers are water-soluble substances which aid in drawing water from the surrounding media and are thereby helpful in manipulating the semi-permeable membrane permeability.
  • Specific examples of flux enhancers are hydroxymethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropyl cellulose, propylene glycol, povidone, or mixtures thereof.
  • passageway covers any suitable means for releasing the contents of the core into the surrounding media.
  • the term includes passages, apertures, bores, holes, or openings that are created through the extended-release coating and form a connection between the core and the surrounding media.
  • the passageway may be created by mechanical drilling or laser drilling, or formed in response to osmotic pressure acting on the drug delivery system. Based on the nature of the desired drug- release profile, the number and diameter of the passageways may be adjusted. At least one orifice is drilled through the membrane on the first drug layer end of the capsule-shaped tablet. However, the diameter of the passageway should not be large enough to allow body fluids to enter the drug delivery system by the process of convection.
  • the blends may be granulated by conventional techniques known in the art such as wet granulation, dry granulation, extrusion-spheronization, or hot melt extrusion.
  • Wet granulation process involves the use of water or any other suitable granulating fluid.
  • Dry granulation may involve the use of a roller compactor or any suitable technique.
  • granulating fluids/solvents for coating include acetone, ethanol, isopropyl alcohol, methylene chloride, or combinations thereof.
  • the trilayered core may be prepared by combining the granule or blend compositions of the drug layers and the push layer using appropriate conventional tooling.
  • the seal coating layer and/or extended-release coating layer may be applied using conventional coating techniques well known in the art such as spray coating in a conventional coating pan or fluidized bed processor, dip coating, melt coating, or compression coating. In a preferred embodiment of the present invention, a spray coating technique may be used. A further additional non-functional coating layer may be applied over the extended-release coating layer.
  • the non-functional coating layer comprises one or more film-forming polymers and coating additives.
  • Coating additives may be selected from the group consisting of plasticizers, coloring agents, and lubricants/glidants.
  • plasticizers examples include polyethylene glycol, triethyl citrate, acetylated triethyl citrate, tributyl citrate, acetylated tributyl citrate, glycerol tributyrate,
  • step 2 The blend of step 1 was granulated with an ethanol and purified water mixture.
  • step 2 The granules of step 2 were lubricated with stearic acid.
  • step 4 The blend of step 4 was granulated with an ethanol and purified water mixture.
  • step 5 The granules of step 5 were lubricated with stearic acid.
  • povidone, polyoxyethylene oxide (Polyox ® WSR-303), sodium chloride, and butylated hydroxyl toluene were sifted and blended.
  • step 7 The blend of step 7 was lubricated with stearic acid.
  • step 3 The granules of step 3, the granules of step 6, and the blend of step 8 were
  • Hydroxy ethyl cellulose was dissolved in an ethanol and purified water mixture.
  • step 9 The trilayered core tablets of step 9 were coated with the solution of step 10.
  • step 14 The coated tablet of step 13 was drilled using a drilling machine to form one
  • step 2 The blend of step 1 is granulated with an ethanol and purified water mixture.
  • step 2 The granules of step 2 are lubricated with magnesium stearate.
  • step 4 The blend of step 4 is granulated with an ethanol and purified water mixture.
  • step 5 The granules of step 5 are lubricated with magnesium stearate.
  • povidone, polyoxyethylene oxide (Polyox ® WSR-303), sodium chloride, butylated hydroxyl toluene, and microcrystalline cellulose are sifted and blended.
  • step 7 is lubricated with magnesium stearate and mixed with iron oxide red.
  • step 9 The granules of step 3, the granules of step 6, and the blend of step 8 are compressed to form trilayered core tablets using appropriate tooling.
  • Hydroxy ethyl cellulose and sodium chloride are dissolved in an ethanol and purified water mixture.
  • step 9 The trilayered core tablets of step 9 are coated with the solution of step 10.
  • Cellulose acetate and polyethylene glycol are dissolved in an acetone and purified water solution.
  • the coated tablet of step 13 is drilled on the first drug layer side to form at least one passageway.
  • the results of the release studies are represented in Table 1 below.
  • Table 1 Percentage (%) of In-Vitro Drug-release in USP Type II Apparatus (Media: 500 mL of modified simulated gastric fluid, pH 1.0 at 50 rpm)

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des comprimés de palipéridone à libération prolongée. L'invention concerne en outre des procédés de préparation desdits comprimés à libération prolongée et des procédés permettant de traiter des troubles neurologiques par l'administration des comprimés précités.
PCT/IB2014/062772 2013-07-01 2014-07-01 Comprimés de palipéridone à libération prolongée et procédés de préparation WO2015001488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1947DE2013 2013-07-01
IN1947/DEL/2013 2013-07-01

Publications (1)

Publication Number Publication Date
WO2015001488A1 true WO2015001488A1 (fr) 2015-01-08

Family

ID=51136537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062772 WO2015001488A1 (fr) 2013-07-01 2014-07-01 Comprimés de palipéridone à libération prolongée et procédés de préparation

Country Status (1)

Country Link
WO (1) WO2015001488A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187176A1 (fr) * 2015-12-29 2017-07-05 Sanovel Ilac Sanayi ve Ticaret A.S. Mini comprimés de palipéridone
CN113616610A (zh) * 2021-07-30 2021-11-09 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
CN114601813A (zh) * 2022-03-30 2022-06-10 深圳市泛谷药业股份有限公司 一种帕利哌酮双层渗透泵缓释制剂及其制备方法
CN114983961A (zh) * 2022-06-30 2022-09-02 苏州中化药品工业有限公司 帕利哌酮缓释片及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
WO1998006380A2 (fr) 1996-08-16 1998-02-19 Alza Corporation Forme galenique destinee a fournir une dose croissante de medicament
WO2004010981A1 (fr) 2002-07-29 2004-02-05 Alza Corporation Techniques et formes de dose d'apport commande de paliperidone
US20050025831A1 (en) 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
US20060204578A1 (en) * 2001-11-06 2006-09-14 Vergez Juan A Dual controlled release dosage form
US20090202631A1 (en) 2002-07-29 2009-08-13 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
WO1998006380A2 (fr) 1996-08-16 1998-02-19 Alza Corporation Forme galenique destinee a fournir une dose croissante de medicament
US20050025831A1 (en) 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US20060204578A1 (en) * 2001-11-06 2006-09-14 Vergez Juan A Dual controlled release dosage form
WO2004010981A1 (fr) 2002-07-29 2004-02-05 Alza Corporation Techniques et formes de dose d'apport commande de paliperidone
US20090202631A1 (en) 2002-07-29 2009-08-13 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATIONAL FONNULARY XVII, 1990, pages 1963 - 1964

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187176A1 (fr) * 2015-12-29 2017-07-05 Sanovel Ilac Sanayi ve Ticaret A.S. Mini comprimés de palipéridone
CN113616610A (zh) * 2021-07-30 2021-11-09 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
CN114601813A (zh) * 2022-03-30 2022-06-10 深圳市泛谷药业股份有限公司 一种帕利哌酮双层渗透泵缓释制剂及其制备方法
CN114983961A (zh) * 2022-06-30 2022-09-02 苏州中化药品工业有限公司 帕利哌酮缓释片及其制备方法
CN114983961B (zh) * 2022-06-30 2024-05-10 苏州中化药品工业有限公司 帕利哌酮缓释片及其制备方法

Similar Documents

Publication Publication Date Title
KR100831181B1 (ko) 1 일 1회 투여로 효과적인 레복세틴 치료를 제공하는 투여형태 및 방법
AU2002314515B2 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US20110027361A1 (en) Extended release dosage form of paliperidone
US20210085654A1 (en) Pharmaceutical composition for modified release
US20050089570A1 (en) Oros push-stick for controlled delivery of active agents
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
US20110281906A1 (en) Sustained release formulation for tacrolimus
US20090227605A1 (en) Enhanced efficacy benzisoxazole derivative dosage forms and methods
TW201318625A (zh) 醫藥組合物
WO2006030402A2 (fr) Dispositif d'administration osmotique a deux compartiments
US20070248671A1 (en) Asymmetric membranes for drug delivery devices
WO2015001488A1 (fr) Comprimés de palipéridone à libération prolongée et procédés de préparation
CA2635767A1 (fr) Comprime multicouche
US8877214B2 (en) Pharmaceutical composition for modified release
WO2006046114A2 (fr) Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
US20180008558A1 (en) Extended release compositions of an aminoalkyl nitrate
KR20060060371A (ko) 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
TW202214246A (zh) 含有氘代丁苯那嗪(deutetrabenazine)之滲透劑型及其使用方法
US8524749B2 (en) Controlled release compositions of tizanidine
US20080194655A1 (en) Zero order controlled release compositions of tizanidine
WO2011018246A2 (fr) Composition de palipéridone à libération contrôlée
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
KR20240055160A (ko) 듀테트라베나진을 포함하는 다중미립자 제형
WO2013168177A2 (fr) Systèmes d'administration de médicament à régulation osmotique
CN112741806A (zh) 一种用于老年痴呆症的缓控释给药系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14736461

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14736461

Country of ref document: EP

Kind code of ref document: A1